Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Learn More

Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations

LEARN MORE

RECENT PRESS RELEASES

06/07/2020 - Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations across Asia Pacific
01/07/2020 - Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
30/06/2020 - FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
30/06/2020 - European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
25/06/2020 - Pfizer Declares Third-Quarter 2020 Dividend
24/06/2020 - Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
22/06/2020 - European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
22/06/2020 - Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
18/06/2020 - Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
18/06/2020 - Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
16/06/2020 - Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
12/06/2020 - Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
11/06/2020 - FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
10/06/2020 - Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
03/06/2020 - Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology